THERE IS AN INCREASED RISK OF HYPERKALAEMIA IF AMILORIDE IS GIVEN CONCOMITANTLY WITH POTASSIUM SUPPLEMENTS OR WITH OTHER POTASSIUM-SPARING DIURETICS. HYPERKALAEMIA MAY ALSO OCCUR IN PATIENTS RECEIVING ACE INHIBITORS, NSAIDS, CYCLOSPORIN, OR TRILOSTANE CONCOMITANTLY. IN PATIENTS RECEIVING AMILORIDE WITH NSAID OR CYCLOSPORIN THE RISK OF NEPHROTOXICITY MAY ALSO BE INCREASED. AMILORIDE MAY ENHANCE THE EFFECTS OF OTHER ANTIHYPERTENSIVE DRUGS. CHANCES OF LITHIUM TOXICITY INCREASES AS ITS RENAL CLEARANCE DECREASES. CHANCES OF HYPERKALEMIA INCREASE WITH COMCOMMITANT USE OF ANGIOTENSIN ENZYME INHIBITOR ANTIHYPERTENSIVES. IN SOME PATIENTS, THE ADMINISTRATION OF A NON- STEROIDAL ANTI-INFLAMMATORY AGENT CAN REDUCE THE DIURETIC, NATRIURETIC, AND ANTIHYPERTENSIVE EFFECTS OF LOOP, POTASSIUM-SPARING AND THIAZIDE DIURETICS. SINCE INDOMETHACIN AND POTASSIUM-SPARING DIURETICS, INCLUDING AMILORIDE HCL, MAY EACH
BE ASSOCIATED WITH INCREASED SERUM POTASSIUM LEVELS, THE POTENTIAL EFFECTS ON
POTASSIUM KINETICS AND RENAL FUNCTION SHOULD BE CONSIDERED WHEN THESE AGENTS ARE
ADMINISTERED CONCURRENTLY.